The FDA will pilot 3 kidney disease therapy devices through the federal watchdog agency’s Innovation Pathway program, aiming to reduce the cost of getting life-saving devices to market.
The watchdog agency selected an implantable renal assist device under development at the University of California in San Francisco, a wearable artificial kidney by Blood Purification Technologies Inc. and a hemoaccess valve system from CreatiVasc Medical.